Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Warfarin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VKORC1 known ✓ | Q9BQB6 | 3/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 10/20 | 0.97 |
| ▸ | ALB | P02768 | 2/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.97 |
| ▸ | PCSK7 | Q16549 | 1/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.75 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.75 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | BRD4 | O60885 | 1/20 | 0.67 |
| ▸ | NQO1 | P15559 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Warfarin SCHEMBL3689 | 0.99 | CYP2C9 (1.00) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL2139452 | 0.99 | CYP2C9 (1.00) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL3792087 | 0.99 | CYP2C9 (1.00) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL29400364 | 0.99 | CYP2C9 (1.00) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL4439794 | 0.99 | CYP2C9 (1.00) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL662875 | 0.99 | CYP2C9 (1.00) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL4757598 | 0.97 | CYP2C9 (0.97) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL34347 | 0.97 | CYP2C9 (0.97) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL2597774 | 0.97 | CYP2C9 (0.97) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL13278154 | 0.97 | CYP2C9 (0.97) | CYP2C9VKORC1ALBHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1738 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087732-A1 | LIQUID, MULTI-DOSE, READY-TO-USE WARFARIN COMPOSITION AND USE | HYLORIS DEVELOPMENTS SA (BE) | 2026-04-30 | — | — | WO | claimed |
| EP-2001450-B1 | DIRECTLY COMPRESSIBLE COMPOSITE FOR ORALLY DISINTEGRATING TABLETS | RUBICON RES PRIVATE LIMITED (IN) | 2019-01-30 | — | — | EP | claimed |
| CN-108685861-A | A kind of warfarin microplate and preparation method thereof | 北京科信必成医药科技发展有限公司 | 2018-10-23 | — | — | CN | claimed |
| CN-104010505-A | Pesticidal compositions and methods related thereto | DOW AGROSCIENCES LLC | 2014-08-27 | — | — | CN | claimed |
| US-8765976-B2 | Polymorphic forms of Warfarin potassium and preparations thereof | APOTEX PHARMACHEM INC. (CA) | 2014-07-01 | — | — | US | claimed |
| CN-101460150-B | Directly compressible compound for orally disintegrating tablets | RUBICON RES PRIVATE LTD | 2014-02-12 | — | — | CN | claimed |
| US-20130143957-A1 | POLYMORPHIC FORMS OF WARFARIN POTASSIUM AND PREPARATIONS THEREOF | APOTEX PHARMACHEM INC. (CA) | 2013-06-06 | — | — | US | claimed |
| EP-2571861-A1 | POLYMORPHIC FORMS OF WARFARIN POTASSIUM AND PREPARATIONS THEREOF | Apotex Pharmachem Inc. (CA) | 2013-03-27 | — | — | EP | claimed |
| WO-2011143747-A1 | POLYMORPHIC FORMS OF WARFARIN POTASSIUM AND PREPARATIONS THEREOF | APOTEX PHARMACHEM INC. (CA) | 2011-11-24 | — | — | WO | claimed |
| US-20090208576-A1 | Orally Disintegrating Tablets | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2009-08-20 | — | — | US | claimed |
| EP-1363893-A1 | PROCESS FOR PURIFICATION OF WARFARIN ACID, WARFARIN ALKALI METAL SALTS AND CORRESPONDING CLATHRATES | TARO PHARMACEUTICALS U.S.A., INC. (US) | 2003-11-26 | — | — | EP | claimed |
| US-6512005-B2 | Process for synthesis of pure warfarin acid, warfarin alkali metal salts and corresponding clathrates | TARO PHARMACEUTICAL INDUSTRIES, LTD. | 2003-01-28 | — | — | US | claimed |
| WO-2002070503-A1 | PROCESS FOR PURIFICATION OF WARFARIN ACID, WARFARIN ALKALI METAL SALTS AND CORRESPONDING CLATHRATES | TARO PHARMACEUTICALS U.S.A., INC. (US) | 2002-09-12 | — | — | WO | claimed |
| US-20020120155-A1 | PROCESS FOR SYNTHESIS OF PURE WARFARIN ACID, WARFARIN ALKALI METAL SALTS AND CORRESPONDING CLATHRATES | TARO PHARMACEUTICAL INDUSTRIES LTD. | 2002-08-29 | — | — | US | claimed |
| EP-0974361-A1 | METHOD OF USING ANTACID AGENT AND PHARMACEUTICAL PREPARATION CONTAINING ANTACID AGENT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-01-26 | — | — | EP | claimed |
| US-5985843-A | PHARMACEUTICAL PREPARATION THAT CONTAINS SUCRALFATE IN THE PRESENCE OF ANOTHER DRUG IN SUCH A WAY THAT THE ANOTHER DRUG IS IMMEDIATELY RELEASED WITHOUT BEING ADSORBED ON OR TRAPPED BY THE SUCRALFATE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1999-11-16 | — | — | US | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0823255-A1 | PHARMACEUTICAL COMPOSITION CONTAINING SUCRALFATE | Chugai Seiyaku Kabushiki Kaisha (JP) | 1998-02-11 | — | — | EP | claimed |
| US-5700410-A | Method of manufacturing wax matrices | NIPPON SHINYAKU CO., LTD. (JP) | 1997-12-23 | — | — | US | claimed |
| EP-0580860-B1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 1997-10-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143957-A1 | POLYMORPHIC FORMS OF WARFARIN POTASSIUM AND PREPARATIONS THEREOF | VKORC1L1, VKORC1, PROC | VKORC1 2/4885CYP2C9 47/4885ALB 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.